Recently, aldehyde dehydrogenase 1 (ALDH1) induction has been found to render lung adenocarcinomas resistant to EGFR-TKIs, and targeting ALDH1 has emerged as a novel strategy for treating lung cancer 2-4. This evidence concerns the gene ALDH1A1 and lung carcinoma.